SUMMARY Nine healthy volunteers were studied on the seventh day of dosing at 2100 h with nizatidine 150 mg (N 150), nizatidine 300 mg (N 300), ranitidine 300 mg (R 300), or placebo, given in a predetermined random order. The double-blind 24 hour studies, using the Royal Free Hospital standard protocol, simultaneously measured intragastric acidity and plasma gastrin concentration. Compared with placebo, subjects responded to dosing with each H2-antagonist by a significant decrease of 24 hour intragastric acidity (N 150 -45%; N 300 -49% R 300 -56%; p<001) and a significant rise of plasma gastrin concentration (N 150+20%; N 300+27%; R 300+58%; p<001).
evening -on 24 hour intragastric acidity in healthy subjects.
In view of the recent interest in the rise of plasma gastrin concentration and human gastric carcinoids,' and the development of enterochromaffinlike cell hyperplasia in some rats treated with high doses of antisecretory drugs,9' ' 24 hour intragastric acidity was correlated in this study with simultaneous measurement of 24 hour plasma gastrin concentration." 12
Methods

SUBJECTS
Nine healthy male volunteers took part in the study: they had a median age of 23 years (range 21-24 years), a median height of 1-80 m (range 1 The subjects were studied under identical conditions for four 24 hour periods, using the Royal Free Hospital protocol for 24 hour studies." During this series of experiments we observed the effect of dosing with drug or placebo at 2100 h, hence the 24 hour studies started at 19 00 h and finished at 18 00 h on the following evening. In order to synchronise feeding and subsequent intragastric acidity before the start of each 24 hour study, the subjects ate a standard lunch at 13 15 h and were then admitted to the research ward at 17 00 h.
A 10 French gauge salem sump nasogastric tube (Argyle Medical) was positioned in the stomach, and from 19 00 h aliquots (5-10 ml) of intragastric contents were aspirated hourly throughout the study. The pH of each aliquot was measured immediately to the nearest 0-01 pH unit by means of a glass electrode and digital pH meter (Radiometer, Copenhagen). The electrode was calibrated with standard buffers (pH 7, 4*01, and 1-09; Radiometer, Copenhagen) before and halfway through each batch of nine samples.
Blood was taken through a venous cannula at hourly intervals between 19 00 h and 18 00 h the next day, except during the night when sampling was omitted at 01 00, 03 00, 05 00, and 07 00 h. Additional samples were taken at 45 and 75 minutes after the start of dinner, breakfast, and lunch. The blood was collected in lithium-heparin glass tubes which contained 0-2 ml aprotinin (Trasylol, Bayer). The tubes were centrifuged immediately, the plasma transferred to plastic tubes and frozen immediately to -20°C. All the plasma samples from each subject were analysed for gastrin in one batch, by radioimmunoassay using antibody GAS 179 in Professor Bloom's laboratory at the Hammersmith Hospital, London.`' This antibody cross-reacts equally with G17 and G34, but does not react with cholecystokinin.
During the study the subjects were fully ambulant around the research ward. The food and environmental conditions for all four studies were identical to those used in earlier studies at the Royal Free Hospital." The following meals were served: dinner, a bedtime snack, breakfast, coffee, lunch, and afternoon tea at 1915, 2215, 0915, 1115, 1315, and 16 15 h respectively.
DOSING
The study was carried out double blind, the dosing being given in a predetermined random order. The subjects were studied on the seventh day of dosing with either placebo, nizatidine 150 mg, nizatidine 300 mg, or ranitidine (Zantac, Glaxo, Greenford UK) The results of plasma gastrin and acidity were also divided into four meal related intervals (22 00-08 00, 09 00-13 00, 13 00-19 00, 19 00-22 00 h). The integrated AUC was calculated for each of these intervals. These results were compared using the Kruskal Wallis non-parametric one-way analysis of variance. In the text 'significant' relates to any difference where p<O-OS. event was reported, and no clinically significant abnormality was detected in routine haematology and biochemistry profiles before and after treatment with each drug regimen.
INTRAGASTRIC ACIDITY Figure 1 shows the median hourly intragastric acidity for the three treatment groups, compared with placebo. Each H2-blocker regimen caused a similar decrease of nocturnal acidity with recovery during the following day. Figure 2 shows that all subjects responded to treatment with an antisecretory drug by a decrease of (p<O-Ol). Table 1 shows the acidity data analysed according to 'meal-related intervals' and that all three drugs caused a significant decrease of nocturnal intragastric acidity, but there was no significant difference between either dose of nizatidine, nor between nizatidine and ranitidine. Neither dose of nizatidine had any effect on daytime acidity, however, whilst ranitidine 300 mg given at 2100 h not only decreased nocturnal acidity, but it also caused a significant decrease of morning intragastric acidity. During treatment with ranitidine 300 mg at 2100 h, intragastric acidity was not significantly different from placebo during the afternoon and early evening.
PLASMA GASTRIN CONCENTRATION Figure 3 shows the median plasma gastrin concentra- Figure 5 shows that there is a significant inverse correlation between the integrated 24 hour intragastric acidity and integrated 24 hour plasma gastrin concentration in these subjects (Spearman rank -0 49; p=0.02). Discussion rougnout tne 24 nours ano F-lgure 4 the The results of this study show that, at steady state, :ed 24 hour plasma gastrin concentration for nizatidine 150 or 300 mg in the evening causes a bject. The subjects responded to dosing with significant decrease in nocturnal intragastric acidity, intagonist by a rise of integrated 24 hour but has no effect on daytime acidity during the gastrin concentration: median 24 hour inte-following day. Earlier experiments have shown that Alasma gastrin concentration was 291 pmolIh/l nizatidine 150-300 mg inhibits nocturnal acid secreebo, 349 and 370 pmol/h/l (+20 and +27%) tion as assessed by continuous aspiration314 (rather tidine 150 mg and 300 mg respectively, and than the hourly sampling of acidity used in the olIh/l (+58%) on rantidine 300 mg -these present study). The present study could detect no -s of 24 hour plasma gastrin concentration significant difference between nizatidine 150 and 300 significant (p<001). mg, suggesting that these doses must be towards the 2 records integrated plasma gastrin concen-top of the dose response curve for this drug. In a iccording to 'meal related intervals'. All three double blind multicentre trial in the United States, aused a significant rise of nocturnal plasma the four week duodenal ulcer healing rates for concentration compared with placebo treat-nizatidine 25 mg bd, 150 mg bd, 300 mg nocte and placebo were 50, 68, and 67%, respectively. 15 In the present study ranitidine 300 mg during the evening caused a similar decrease of nocturnal acidity to either dose of nizatidine. If it is true that control of nocturnal acidity relates closely to duodenal ulcer healing at four weeks,'6 it could be anticipated that nizatidine 300 mg nocte will be similar (in terms of ulcer healing) to rantidine 300 mg nocte. The only published controlled study in 777 patients reported four week duodenal ulcer healing rates of 81 and 80%, and eight week healing rates of 92 and 93%, for nizatidine 300 mg and ranitidine 300 mg nocte, respectively.T here are three potential disadvantages of decreasing intragastric acidity in man: allowing pathogens access to the small and large intestine,P lacebo 150 300 300 allowing bacterial proliferation in the stomach,'9 and Nizatidine (mg) . the evening can control nocturnal acidity, with essentially normal daytime acidity. The normal intragastric acid present during the daytime should ensure not only the 'sterilisation' of pathogens in the main meals of the day, but it should eliminate any chance of bacterial colonisation in the stomach. Every subject responded in this study to dosing with either nizatidine or ranitidine by a decrease of integrated 24 hour intragastric acidity (Fig. 2) and by a rise of integrated 24 hour plasma gastrin concentration (Fig. 4) . There was a significant inverse correlation between intragastric acidity and plasma gastrin concentration (Fig. 5) . Similar results have been observed during treatment with ranitidine 150 mg bid, omeprazole 20 mg om,'2 and famotidine 40 mg nocte.2" Although all these antisecretory drugs cause a significant rise of plasma gastrin concentration, the degree of elevation is mild compared with that observed in patients with pernicious anaemia." Of these drug regimens, nizatidine 150 and 300 mg at 2100 h have the shortest duration of antisecretory activity and they cause the least rise in 24 hour plasma gastrin concentration. Cimetidine 800 mg or 400 mg nocte are also short acting antisecretory regimens, but neither has been tested under the conditions of the Royal Free Hospital standard protocol for 24 hour intragastric acidity and plasma gastrin concentration.
A~~~~~~~~~1
In conclusion, evening administration-of nizatidine 150 or 300 mg, or ranitidine 300 mg, cause similar decreases of nocturnal acidity, with associated nocturnal elevation of plasma gastrin concentration. Ranitidine 300 mg has a longer duration of action than the other dosing regimens, causing changes of acidity and plasma gastrin not only in the night but also the morning. Capsules containing placebo, nizatidine and ranitidine were supplied by Drs P Keohane and Dr R John of Eli Lilly and Company, who also provided financial support for the study. (6) pA/cm2 for control biopsies and 10-5 (3.1) (4) pA/cm2 for CF biopsies (p>0O05).
ted by jejunal biopsies from CF children (Figure) , an effect that was not significantly different from the response obtained in biopsies from a control group.
It therefore appears that the increased SCC across CF jejunum induced by A23187 is unlikely to result from the opening of basolateral K+ channels alone, but could represent a Cl-secretory response brought about by the elevation of intracellular Ca2 . Patch clamp analysis of the luminal membranes of enterocytes affected by CF would provide a more definitive answer to this problem.
